BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide derived from a protein sequence found naturally in human gastric juice
Adquey and Bysanti are tactical but meaningful portfolio additions, competing in large, established categories where formulation, tolerability, and commercial execution determine uptake more than class novelty
Improved glucose and insulin tolerance results in decreasing serum level of cholesterol, TG, and free fatty acid [136]
The research record is frequently overstated because studies of BPC-157, full-length thymosin beta-4 and the seven-residue TB-500 fragment are blended together as though they involved the same material
Marketed by: Fusion Cosmeceutics Private Limited, 106 Maker Bhavan No
JPMorgan researchers estimate that the number will balloon, with 30 million people expected to be taking GLP-1 drugs by 2030, or around 9 percent of the US population